SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back




Title
: Conversations in Dermatology May 19, 2018
Activity/Course #:
: 05.19.18CID

Cost:
: Free
Release/Start Date:
: May 19 2018
Expiration Date:
: May 19 2018
Topics:
: Dermatology
Target Audience:
: Dermatologists and Primary Care Providers
Format:
: Live Virtual Conferences
Estimated Time To Complete CME Activity:
: 2.5 hours
Credit(s):
: 2.5 AMA PRA Category I Credit(s)
2.5 AANP Contact hour(s) which includes 1.5 pharmacology hour(s)
Hardware/Software Requirements:

There is no registration fee for this CME live virtual conference!

June 23, 2018
Broadcast Live from Ft. Lauderdale, FL
Start Time: 8:00 am EST

Program Summary:

Primary care providers face complex challenges everyday in their busy practices. With rapid changes in medicine, staying informed about new developments can be equally challenging. Our goal in this CME activity is to help you hone your skills in the diagnosis and management of patients with varied conditions you are likely encountering in your practice.

We have recruited a faculty of well-known thought leaders and experienced teachers who, as clinicians themselves, understand the challenges you face every day as a primary care provider. Our faculty will be at your disposal to provide evidence-based science, current treatment guidelines, discuss challenging cases, and provide answers for you that can ultimately lead to better health care for your patients. The presentations will include several interactive cases and discussion sessions to keep you actively learning.

Please join us and become an active participant in this one-day learning community of your peers.

 

Learning Objectives:

At the conclusion of this program, participants should be able to:

1. Describe the newer concepts in the pathophysiology of asthma and type 2 inflammation, and the implications of biologic therapies in the era of precision medicine; Determine the utility of simple biomarkers to identify patients who are candidates for targeted biologic therapies and appropriate referral; Discuss the impact of comorbid conditions on asthma control and the evidence-based approach to their treatment; Discuss the paradigms of multidisciplinary care in asthma, with an emphasis on patient and provider education, to improve adherence to inhalers and emerging biologic therapies in asthma.

2. Recognize the pathogenesis of type 2 diabetes (T2DM) as a progressive, multi-defect disorder; Discuss the strengths and limitations of current guidelines for diabetes management; Successfully use strategies for adherence to multiple medications to improve outcomes in diabetes; Examine data on current combination strategies to choose therapies that most effectively address a patient’s underlying pathophysiologic needs.

3. Discuss clinician and patient barriers to initiation and intensification of insulin therapy; Recognize the prevalence and clinical impact of hypoglycemia in special populations at risk; Discuss the pharmacology and clinical differences between existing and new long-acting and concentrated insulins; Discuss how to incorporate new basal and concentrated insulins into clinical practice while minimizing the risk of adverse events.

4. Review and characterize the clinical features of atopic dermatitis (AD); Discuss the current immuno-pathophysiology of AD; Identify strategies for comprehensive treatment of atopic dermatitis in pediatric and adult populations; Update and position emerging topical therapies as well as up and coming targeted biologic agents as a new treatment category for AD.

5. Review the risk factors and classification of pulmonary hypertension (PH); Discuss the appropriate diagnostic strategy for pulmonary arterial hypertension (PAH), including the roles of echocardiography, ventilation/perfusion (V/Q) scanning, and right heart catheterization (RHC); Review current and emerging treatments for patients with PAH; Describe how to monitor patients with PAH for disease progression.


    Agenda*

    8:00-8:10 AM
     

    Welcome Remarks
    Gregg Sherman, MD

    8:10-9:20 AM   The Role of Type 2 Inflammation in Severe Persistent Asthma:
    Integrating Biologic Therapy to Optimize Outcomes
    Sandra G. Adams, MD, MS
    9:25-10:35 AM   The Progression of Type 2 Diabetes: A Rational Approach for Long Term Disease
    Management
    Mark Stolar, MD
    10:35-10:50 AM

    Break

    10:50-12:00 AM

    Safely Achieving Goals in Type 2 Diabetes (T2DM): The Role of Concentrated and Long-Acting Insulins
    Mark Stolar, MD
     12:00-12:30 PM
      Lunch
     12:30- 1:40 PM
      
    Atopic Dermatitis: New Insights, New Therapies
    Brad P. Glick, DO, MPH, FAOCD
     1:45-2:55 PM
     Evolving Strategies of Care in Pulmonary Arterial Hypertension:
    Integrating the Data into Practice
    Franck Rahaghi, MD, MHS, FCCP
     2:55-3:00 PM
     Program Summary and Closing Remarks
    Gregg Sherman, MD


    * Subject to Change

    Faculty
    Sandra G. Adams, MD, MS
    Professor, Division of Pulmonary Diseases and Critical Care Medicine
    UT Health San Antonio
    Staff Physician, The South Texas Veterans Health Care System
    Founder, President
    WipeDiseases Foundation
    San Antonio, TX

    Brad P. Glick, DO, MPH, FAOCD
    Director, South Florida Psoriasis Treatment Centers
    Clinical Assistant Professor of Dermatology
    FIU Herbert Wertheim College of Medicine
    Miami, FL

    Franck Rahaghi, MD, MHS, FCCP
    Director of Advanced Lung Disease Clinic
    Director, Pulmonary Hypertension Clinic
    Chairman, Dept. of Pulmonary and Critical Care
    Cleveland Clinic Florida...Franck Rahaghi, MD, MHS, FCCP
    Director of Advanced Lung Disease Clinic
    Director, Pulmonary Hypertension Clinic
    Chairman, Dept. of Pulmonary and Critical Care
    Cleveland Clinic Florida
    Weston, FL

    Mark Stolar, MD
    Associate Professor of Clinical Medicine
    Northwestern University Medical School
    Chicago, IL

    Planning Committee
    Gregg Sherman, MD
    Chief Medical Officer/Course Director
    National Association for Continuing Education
    Plantation, FL

    Sheila Lucas, CWEP
    Activity Director
    National Association for Continuing Education
    Plantation, FL

    Sandy Bihlmeyer, M.Ed.
    Senior Project Manager
    National Association for Continuing Education

    Plantation, FL

    Michelle Frisch, MPH, CHCP
    National Association for Continuing Education
    Plantation, FL

    Harvey C. Parker, Ph.D., CHCP
    National Association for Continuing Education
    Plantation, FL

Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 2.5 Contact hour(s) of continuing education which includes 1.50 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosure will be provided in the activity materials.
Commercial Support
This activity is supported by Sanofi Genzyme and Regeneron Pharmaceuticals.